Top of this page
Skip navigation, go straight to the content

Neupro® (Parkinson's disease)

In Europe, Neupro® is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on-off" fluctuations).

Neupro® may be prescribed for use in adults and elderly.

Neupro® (Restless Legs Syndrome)

In Europe, Neupro® is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in adults.